Diversity, Versatility and Leukaemia

$110.00

Geoffrey Brown
College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK

Isidro Sanchez-Garcia
Senior Staff Researcher, IBMCC-CSIC/University of Salamanca, Salamanca, Spain

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

The blood cell system has provided a model system that has been used by many researchers to investigate how a stem cell can give rise to a wide variety of mature cell types. The principles that emerged in developmental biology have been applied to the structure of tissues throughout the body. However, many of the principles have been challenged by recent findings, changing the way we view blood cell development. In turn, this has impacted our understanding of the origin and nature of leukaemia, as well as cancer in general. Like the development of any body tissue, cancer is an organised and hierarchical tissue with its own identity. A new viewpoint is that the mutations that give rise to cancer re-programme cancer cells to their own abnormal pattern of tissue development. Understanding how the hierarchy of tumour identity differs from that of normal tissue provides important new avenues to the development of new treatments for cancer. No doubt further refinement to our understanding of normal and cancer cells will continue for many years to come. Even so, we appear to be moving towards an exciting prospect of providing the key to unlocking the long standing mystery of primary cellular events that undermine and distort our normal cells and give rise to the disease of cancer. The importance of this is the prospect of developing new treatments for cancer. In particular, the distorted behaviour of cancer cells might be reversible so that they can be restored to their normal state. Diversity, Versatility and Leukaemia examines how normal and cancer cells are inextricably linked, and focuses on the changes to how we view the development of normal cells and the subversion of this process in cancer.
(Imprint: Nova Biomedical)

Clear

Details

Table of Contents

Preface

Short Abstract

Acknowledgments

Chapter 1. The Diversity of Blood Cells

Chapter 2. The Conventional Viewpoint to Haematopoiesis

Chapter 3. Revision to the Model of Haematopoiesis

Chapter 4. Classifying the Various Leukaemias/Haematopoietic Cancers

Chapter 5. Leukaemia/Haematopoietic Cancer-initiating Cellular Events

Chapter 6. Leukaemia/Haematopoietic Cancers and Lineage Commitment

Chapter 7. The Prospect of New Treatments for Leukaemia and Other Cancers

Authors’ Contact Information

Index


Reviews

“Based largely on technological advances allowing single cell transcriptomic and proteomic analyses, our accepted concepts of tumour biology are undergoing revolutionary changes. This book, written by two world leaders in experimental haematology, provides an excellent comprehensive account of how our views on tumours of white blood cells (leukaemias) have to be modified.” – Professor Rhodri Ceredig, MB, ChB, PhD, FRCPath, Director, National Centre for Biomedical Engineering Science, Galway, Ireland

“Our knowledge on biology of hematopoietic progenitors and leukemogenesis is constantly evolving, changing our concepts on these processes. In this book, two experts in the field, provide comprehensive summary on new discoveries in hematopoiesis and leukemogenesis, emphasizing versatile functions of HSCs and HPCs as well as cancer stem cells, in these processes and potential application of new knowledge on therapy of leukemia.” – Izidore S. Lossos M.D., Director, Lymphoma Program, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida

“This excellent book provides a critical review of current progress towards a better understanding of the cellular and molecular mechanisms of normal bone marrow function and the development of various forms of leukaemia. While stressing the complexity of this rapidly moving field of research it offers valuable insights into its future therapeutic possibilities. It will be of great value, not only to hematologists, but to workers in any form of malignant disease.” – Professor Sir David Weatherall, KBE FRS FMedSci, The Weatherall Institute of Molecular Medicine, University of Oxford


We believe that our book will be of great interest to A) teaching activities at undergraduate and postgraduate levels at universities (Schools of Medicine, Biological Science, etc) and to B) a number of junior (postdoctoral) and senior researchers including (i) medical doctors, due to the importance of an understanding of normal stem cells and Cancer Stem Cells to both the preclinical and clinical fields; (ii) stem cell researchers because of their intrinsic interest in the principles that govern the behaviour of normal stem cells and CSCs and their importance to biology, (iii) cancer biologists due to the implications of the results discussed in the book to the development of an understanding of the underlying problem in cancer development and (iv) Pharma companies due to the implications of the new ideas to drug discovery.

Additional information

Binding

,